Skip to content

Intervention and Efficacy Evaluation Study of Combined Modality Therapy in Patients with Biliary Atrisia after Kasai Operationru

Intervention and Efficacy Evaluation Study of Combined Modality Therapy in Patients with Biliary Atrisia after Kasai Operationru

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-09000331
Enrollment
Unknown
Registered
2009-02-11
Start date
2007-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Atresia

Interventions

group 1:Given Yinzhihuang with Ligustrazine from the day 3 after operation
group 2:Given Yinzhihuang with placebo from the day 3
group A:Divide two groups according different glucocorticoid, group A is given dexamethasone from the seventh day after operation
group B:Divide two groups according different glucocorticoid, group B is given methylprednisolone from the seventh day after operation

Sponsors

The First Affiliated Hospital of Sun Yat Sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patient be diagnosd as biliary atresia and has underwent Kasai procedure; 2. The bile drainage is well postoperation; 3. The age is less than 90 days; 4. Informed consents and willing to participant; signed the informed consent form accords with ethics principles.

Exclusion criteria

Exclusion criteria: 1. The patient has little bile drainage postoperation; 2. Patient cannot tolerate the therapy for all reasons; 3. The patient and their family reject to participart the trial.

Design outcomes

Primary

MeasureTime frame
the color of faeces, skin of forehead and sclera;the size, hardness, edge of liver and the size of spleen; the evidence of portal hypertension;The degree of liver fibrosis;total bilirubin, direct bilirubin, the ratio of direct bilirubin to indirect bilirubin;

Countries

China

Contacts

Public ContactLiu Juncheng
liujcgd@tom.com+86 0 13543466640

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026